Fujian Cancer Hospital (Fujian Cancer Institute, Fujian Cancer Prevention and Treatment Center)

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA

Not Applicable

Conditions: Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction

Interventions: Drug: Fluorouracil
Drug: Irinotecan
Drug: Oxaliplatin
Drug: Paclitaxel
Drug: calcium levofolinate

First Posted Date: 2017-02-07

Last Posted Date: 2017-02-07

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 150

Registration Number: NCT03045770

Locations: 🇨🇳
Jianwei Yang, Fuzhou, Fujian, China

Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA

Phase 2

Conditions: Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction

Interventions: Drug: Apatinib
Drug: Irinotecan

First Posted Date: 2017-01-25

Last Posted Date: 2017-01-25

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 74

Registration Number: NCT03030937

Locations: 🇨🇳
Jianwei Yang, Fuzhou, Fujian, China

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC

Phase 3

Conditions: EGFR Gene Mutation

Interventions: Drug: pemetrexed
Drug: cisplatin
Drug: Erlotinib

First Posted Date: 2016-09-01

Last Posted Date: 2016-09-01

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 120

Registration Number: NCT02886195

The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients

Phase 3

Conditions: Breast Cancer
Angiogenesis

Interventions: Drug: endostar

First Posted Date: 2016-08-12

Last Posted Date: 2016-08-12

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 80

Registration Number: NCT02865304

POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC

Phase 2

Completed

Conditions: Malignant Neoplasm of Stomach Stage IV

Interventions: Drug: POF
Drug: FOLFOX
Drug: FOLFOX plus PAC(ip)

First Posted Date: 2016-07-27

Last Posted Date: 2021-04-23

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 90

Registration Number: NCT02845908

Locations: 🇨🇳
Rongbo Lin, Fuzhou, Fujian, China

Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer

Phase 2

Conditions: Malignant Neoplasm of Stomach Stage II

Interventions: Drug: Apatinib
Drug: Paclitaxel-based chemotherapeutic regimens

First Posted Date: 2016-03-03

Last Posted Date: 2018-10-17

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 20

Registration Number: NCT02697838

Locations: 🇨🇳
Rongbo Lin, Fuzhou, Fujian, China

Comparison of Short Term Outcomes Between Totally Laparoscopic and Laparoscopy-Assisted Distal Gastrectomy With Billroth-II Reconstruction and D2 Lymphadenectomy for Locally Advanced Gastric Cancer

Not Applicable

Conditions: Total Laparoscopic Distal Gastrectomy
Locally Advanced Gastric Cancer

Interventions: Procedure: TLDG or LADG

First Posted Date: 2015-02-19

Last Posted Date: 2015-04-27

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 176

Registration Number: NCT02365896

Intensity Modulated Radiotherapy in Recurrent T1-2 Nasopharyngeal Carcinoma

Not Applicable

Completed

Conditions: Nasopharyngeal Cancer Recurrent

Interventions: Radiation: 3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT

First Posted Date: 2014-04-14

Last Posted Date: 2014-04-14

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 168

Registration Number: NCT02113423

Locations: 🇨🇳
Fujian Cancer Hospital Radiation Oncology Department, Fuzhou, Fujian, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy